Unlock advanced weight loss results with Retatrutide — a next-generation triple hormone receptor agonist that goes beyond traditional GLP-1 and even GLP-1 + GIP therapies. Retatrutide activates GLP-1, GIP, and glucagon receptors, creating a more comprehensive metabolic effect. Because of this added glucagon activity, Retatrutide may support greater fat loss and higher energy burn compared to other GLP-1-based therapies.In clinical studies, Retatrutide has demonstrated significant weight loss results, with some participants losing over 20% of their body weight.

Retatrutide is currently an investigational medication and has not yet been approved by the FDA for weight loss. Compounded Retatrutide is not evaluated by the FDA for safety, effectiveness, or quality.